1618095-18-3

Basic information

• Product Name: N-hydroxy-3-(4-(5-(2-(1-naphthyl)ethyl)-1,3,4-oxadiazol-2-yl)phenyl)acrylamide
• CAS NO: 1618095-18-3
• Molecular Weight: 385.422
• Mol File: 1618095-18-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-hydroxy-3-(4-(5-(2-(1-naphthyl)ethyl)-1,3,4-oxadiazol-2-yl)phenyl)acrylamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-hydroxy-3-(4-(5-(2-(1-naphthyl)ethyl)-1,3,4-oxadiazol-2-yl)phenyl)acrylamide(1618095-18-3)
• EPA Substance Registry System: N-hydroxy-3-(4-(5-(2-(1-naphthyl)ethyl)-1,3,4-oxadiazol-2-yl)phenyl)acrylamide(1618095-18-3)

Safety Data

• Hazardous Substances Data: 1618095-18-3(Hazardous Substances Data)

Upstream product

• 1618094-79-3 C₂₃H₁₈N₂O₃ 
• 1618094-58-8 C₂₇H₂₆N₂O₃ 
• 39115-95-2 4-iodobenzohydrazide 
• 1618094-36-2 C₂₀H₁₅IN₂O 
• 3243-42-3 1-Naphthalenepropanoic acid 

Relevant articles and documents

1,3,4-Oxadiazole-containing histone deacetylase inhibitors: Anticancer activities in cancer cells

We describe 1,3,4-oxadiazole-containing hydroxamates (2) and 2-aminoanilides (3) as histone deacetylase inhibitors. Among them, 2t, 2x, and 3i were the most potent and selective against HDAC1. In U937 leukemia cells, 2t was more potent than SAHA in inducing apoptosis, and 3i displayed cell differentiation with a potency similar to MS-275. In several acute myeloid leukemia (AML) cell lines, as well as in U937 cells in combination with doxorubicin, 3i showed higher antiproliferative effects than SAHA.